Mirhosseini-Holmes-Walton syndrome

Mirhosseini-Holmes-Walton syndrome (also known as Mirhosseini syndrome or microcephaly-pigmentary retinopathy-intellectual disability syndrome) is an extremely rare autosomal recessive disorder characterized by the triad of microcephaly, pigmentary retinal degeneration, and intellectual disability. The condition was first described in 1972 and affects multiple body systems, primarily the central nervous system and the eyes. Affected individuals typically present in infancy or early childhood with microcephaly (abnormally small head), moderate to severe intellectual disability, and progressive pigmentary retinopathy leading to visual impairment. Additional features that have been reported include cataracts, short stature, and in some cases, hypogonadism. The retinal changes resemble retinitis pigmentosa and may lead to progressive vision loss over time. There is no specific cure or targeted treatment for Mirhosseini-Holmes-Walton syndrome. Management is supportive and symptomatic, focusing on early developmental intervention, special education services, ophthalmologic monitoring and management of visual impairment, and addressing any associated complications. Regular follow-up with a multidisciplinary team including neurologists, ophthalmologists, and developmental specialists is recommended. The molecular genetic basis of this condition remains poorly characterized, and very few cases have been reported in the medical literature.

Common questions about Mirhosseini-Holmes-Walton syndrome